# US 2021/0330813 A1 · Rnai induced c9orf72 suppression for the treatment of als/ftd

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330813 A1
- Document ID: US20210330813A1
- Status: Published application
- Kind: A1
- Application number: 17/196,531
- Filed: 2021-03-09
- Published: 2021-10-28
- Earliest claimed: 2018-09-12
- Applicants: Uniqure IP B.V.
- Inventors: Raygene Michaël MARTIER; Pavlina Stefanova KONSTANTINOVA
- Web page: https://patentgrep.com/patent/US20210330813A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides for specific target RNA sequences that can in particular be applied in RNAi based gene therapy approaches for the treatment of ALS and/or FTD. These specific target RNA sequences were found by selecting target RNA sequences that were conserved in the C9ORF72 target RNA sequence and were shown to provide for efficient silencing. Also are provided combinations of target RNA sequences that are useful in the treatment of ALS and/or FTD.

## Claims

### Claim 1

An expression cassette encoding a double stranded RNA comprising:
a first RNA sequence, wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is substantially complementarity to SEQ ID NO. 32 and to a target RNA sequence comprised in an RNA encoded by a human C9orf72 gene, and
a second RNA sequence,
wherein the first and second RNA sequence are substantially complementary.

### Claim 2 (depends on 1)

The expression cassette according to claim 1, wherein the first and second RNA sequences are comprised in a pre-miRNA scaffold, a pri-miRNA scaffold or a shRNA.

### Claim 3 (depends on 1)

The expression cassette according to claim 1, wherein the first and second RNA sequences are comprised in a pre-miRNA scaffold or a pri-miRNA scaffold from miR101 or miR451.

### Claim 4 (depends on 1)

The expression cassette according to claim 1, wherein the first RNA sequence is comprised in a guide sequence.

### Claim 5 (depends on 1)

The expression cassette according to claim 1, wherein the first RNA sequence and the second RNA sequence, when expressed in a cell, are processed by the cell to produce a guide sequence comprising the first RNA sequence.

### Claim 6 (depends on 1)

The expression cassette according to claim claim 1, wherein the first RNA sequence is SEQ ID NO. 86 or SEQ ID NO. 91.

### Claim 7 (depends on 6)

The expression cassette according to claim 6, wherein the first RNA sequence and second RNA sequence are selected from the group consisting of the combinations of SEQ ID NOs. 86 and 121, and SEQ ID NOs. 91 and 122 or 157.

### Claim 8 (depends on 7)

The expression cassette according to claim 7, wherein the encoded RNA comprises an RNA sequence selected from the group consisting of SEQ ID NOs. 123, 124, 141, 142 and 158.

### Claim 9 (depends on 1)

An expression cassette, comprising a combination of a first and second RNA sequence as defined in claim 1 and encoding a second double stranded RNA, the second double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence of the second double stranded RNA are substantially complementary, and wherein the first RNA sequence of the second double stranded RNA has a sequence length of at least 19 nucleotides and is substantially complementarity to a target RNA sequence comprised in an RNA encoded by a human C9orf72 gene, and wherein said first RNA sequence of said second double stranded RNA is substantially complementary to a target RNA sequence comprised in antisense RNA transcripts encoded by the human C9orf72 gene, wherein said antisense RNA transcript target sequence preferably is SEQ ID NO. 15 or SEQ ID NO. 21.

### Claim 10 (depends on 1)

The expression cassette according to claim 1, wherein the expression cassette comprises a PGK promoter, a CMV promoter, a neurospecific promoter or a CBA promoter operably linked to the first RNA sequence and the second RNA sequence.

### Claim 11 (depends on 1)

A gene therapy vector, comprising the expression cassette according to claim 1.

### Claim 12 (depends on 11)

The gene therapy vector according to claim 11, wherein vector is an AAV vector.

### Claim 13 (depends on 12)

The gene therapy vector according to claim 12, wherein the first and second RNA sequences, when expressed in a cell, reduce expression of RNA encoded by a human C9orf72 gene both in the cell nucleus as in the cytoplasm.

### Claim 14 (depends on 12)

The gene therapy vector according to claim 12, wherein the first and second RNA sequences, when expressed in a cell, reduce expression of G4C2 foci and/or G2C4 foci.

### Claim 15 (depends on 11)

A method of treating ALS and/or FTD, comprising administering to a subject in need thereof a gene therapy vector according according to claim 11.
